GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Insulet Corp (NAS:PODD) » Definitions » Cyclically Adjusted PB Ratio

PODD (Insulet) Cyclically Adjusted PB Ratio : 47.53 (As of Jun. 24, 2025)


View and export this data going back to 2007. Start your Free Trial

What is Insulet Cyclically Adjusted PB Ratio?

As of today (2025-06-24), Insulet's current share price is $308.465. Insulet's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was $6.49. Insulet's Cyclically Adjusted PB Ratio for today is 47.53.

The historical rank and industry rank for Insulet's Cyclically Adjusted PB Ratio or its related term are showing as below:

PODD' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 21.34   Med: 57.15   Max: 118.98
Current: 47.42

During the past years, Insulet's highest Cyclically Adjusted PB Ratio was 118.98. The lowest was 21.34. And the median was 57.15.

PODD's Cyclically Adjusted PB Ratio is ranked worse than
99.6% of 500 companies
in the Medical Devices & Instruments industry
Industry Median: 1.86 vs PODD: 47.42

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Insulet's adjusted book value per share data for the three months ended in Mar. 2025 was $18.912. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $6.49 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Insulet Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Insulet's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Insulet Cyclically Adjusted PB Ratio Chart

Insulet Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 104.69 83.35 75.20 47.21 43.63

Insulet Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.06 38.60 41.58 43.63 40.47

Competitive Comparison of Insulet's Cyclically Adjusted PB Ratio

For the Medical Devices subindustry, Insulet's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Insulet's Cyclically Adjusted PB Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Insulet's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Insulet's Cyclically Adjusted PB Ratio falls into.


;
;

Insulet Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Insulet's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=308.465/6.49
=47.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Insulet's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Insulet's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=18.912/134.9266*134.9266
=18.912

Current CPI (Mar. 2025) = 134.9266.

Insulet Quarterly Data

Book Value per Share CPI Adj_Book
201506 1.235 100.684 1.655
201509 0.969 100.392 1.302
201512 0.598 99.792 0.809
201603 0.462 100.470 0.620
201606 0.479 101.688 0.636
201609 1.134 101.861 1.502
201612 1.099 101.863 1.456
201703 1.098 102.862 1.440
201706 1.115 103.349 1.456
201709 1.277 104.136 1.655
201712 2.718 104.011 3.526
201803 2.905 105.290 3.723
201806 3.038 106.317 3.856
201809 3.351 106.507 4.245
201812 3.583 105.998 4.561
201903 3.750 107.251 4.718
201906 4.153 108.070 5.185
201909 2.437 108.329 3.035
201912 1.211 108.420 1.507
202003 0.936 108.902 1.160
202006 8.586 108.767 10.651
202009 9.033 109.815 11.099
202012 9.143 109.897 11.225
202103 8.840 111.754 10.673
202106 6.691 114.631 7.876
202109 7.224 115.734 8.422
202112 8.041 117.630 9.223
202203 6.444 121.301 7.168
202206 6.088 125.017 6.571
202209 6.164 125.227 6.641
202212 6.854 125.222 7.385
202303 7.214 127.348 7.643
202306 7.935 128.729 8.317
202309 8.700 129.860 9.039
202312 10.481 129.419 10.927
202403 11.292 131.776 11.562
202406 14.240 132.554 14.495
202409 15.939 133.029 16.166
202412 17.260 133.157 17.489
202503 18.912 134.927 18.912

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Insulet  (NAS:PODD) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Insulet Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Insulet's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Insulet Business Description

Traded in Other Exchanges
Address
100 Nagog Park, Acton, MA, USA, 01720
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetics are using it worldwide.
Executives
John W. Kapples officer: SVP, Secretary and GC C/O GCP APPLIED TECHNOLOGIES INC., 62 WHITTEMORE AVENUE, CAMBRIDGE MA 02140
Eric Benjamin officer: SVP, R&D, New Prod Dev. & Comm C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DR, SUITE 200, BILLERICA MA 01821
Jessica Hopfield director C/O 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Frederick Wayne A.i. director 500 W MAIN ST., LOUISVILLE KY 40202
Lauren Budden officer: VP, CAO and Controller C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Luciana Borio director C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BLVD., SUITE 315, WOODCLIFF LAKE NJ 07677
Timothy J Scannell director 2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002
Mark N Field officer: SVP & Chief Technology Officer C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Prem Singh officer: SVP, Global Operations C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Shacey Petrovic officer: CCO 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
James Hollingshead director C/O RESMED INC., 9001 SPECTRUM CENTER BOULEVARD, SAN DIEGO CA 92123
Wayde D. Mcmillan officer: EVP, CFO C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Dan Manea officer: SVP, Chief HR Officer C/O INSULET CORPORATION, 100 NAGOG PARK, ACTION MA 01720
Michael R Minogue director 22 CHERRY HILL DR, C/O ABIOMED INC, DANVERS MA 01923
Laetitia Cousin officer: SVP, Reg, Quality & Compliance C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720